Lumosa Therapeutics and Skyline Vet Pharma announced a licensing agreement for Lumosa's CS011. According to the terms, SVP will develop and commercialize Lumosa's CS011, an extended-release analgesic injection, in the Territory (North America, Australia and New Zealand) for pain management in companion animals. Under the agreement, SVP receives exclusive rights to the development, commercialization, and marketing of CS011 (designated as SVP-161 by SVP) in the above-mentioned Territory. Lumosa will receive license fee, regulatory and sales milestones payments, plus royalties based on the sales of the product. SVP is responsible for animal clinical studies required for product registration, regulatory submissions for market approval, and marketing activities in the Territory. SVP-161 (CS011) is a prodrug of nalbuphine, a kappa-agonist and partial mu-antagonist analgesic that relieves moderate to severe pain and has ceiling effect in terms of respiratory depression. It has a unique efficacy and safety profile among opioid analgesics. If successfully developed, SVP-161 will offer veterinary professionals a better choice in pain management for companion animals. The starting and ending dates of the contract or commitment is January 16, 2018 to May 27, 2036. Lumosa will receive an upfront payment of USD 0.2 million upon signing the agreement and milestone payments, together up to USD 8 million, plus royalties based on the sales of the product. SVP obtains exclusive rights of development, commercialization, and marketing of the product in the United States, Canada, Australia and New Zealand in the field of veterinary use only. SVP will be responsible for applying for INAD (Investigational New Animal Drug), completing premarketing clinical trials (including Pharmacokinetics studies, dose range finding, efficacy and safety studies) and NADA (New Animal Drug Application), obtaining market authorization and marketing & sales in the licensed territories. The milestone payments and royalties are subject to the progress of the premarketing clinical trials, product registration and the sales of the product. There will be positive impact to Lumosa¡¦s short-term and long-term finances and operation.